COMMUNIQUÉS West-GlobeNewswire

Artiva Biotherapeutics Announces Strategic Update and Discontinues Development of AlloNK®
27/10/2026
Company halting further development of AlloNK® (AB-101), including the planned phase 3 pivotal trial Updated deep B cell depletion and clinical response data is consistent with previously reported findings; however, [...]
InflaRx Announces November Investor Events
27/10/2026
Jena, Germany, Oct. 27, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced its events calendar [...]
Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution
27/10/2026
– ARCALYST ® (rilonacept) Q3 2026 net product revenue of $286.0 million, representing ~58% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $1.045 - $1.050 billion – – KPL-387 pivotal [...]
Peptide Stacks: Kylo Peptides Brings Wolverine, GLOW and KLOW Into One Research Stack Line
27/10/2026
Sheridan, Wyoming, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Kylo Peptides [ https://kylopeptides.com/ ] has combined its Wolverine, GLOW, and KLOW peptide stacks into a single research stack line in its catalog. The company [...]
Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131
27/10/2026
Durable Complete Response Achieved with Single Administration of Iopofosine I 131 Provides Additional Clinical Support for the Differentiated Mechanism of Action of Iopofosine I 131 and its Potential Utility Across a [...]
Mammogen and MammoLink Partner to Advance a New Model for Community-Based Breast Cancer Detection
27/10/2026
MammoLink joins Mammogen’s KATELYN-ERIN trial, expanding community access to a prospective study evaluating blood-based RNA biology for breast cancer detection NEWPORT BEACH, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- [...]
Cullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDA
27/10/2026
Global regulatory clearances in the U.S. and Australia support initiation of a Phase 1b/2a study in relapsing and refractory ITP and wAIHA Study expands immunology portfolio into autoimmune cytopenias, evaluating a [...]
Fortrea to Participate in Jefferies Global Healthcare Conference
27/10/2026
DURHAM, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor [...]
Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference
27/10/2026
SAN DIEGO and SUZHOU, China, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel [...]
Bioventus to Report Third Quarter of Fiscal Year 2026 Financial Results on November 2, 2026
27/10/2026
DURHAM, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for [...]
Iovance Biotherapeutics to Report Third Quarter 2026 Financial Results and Corporate Updates on Thursday, November 5, 2026
27/10/2026
PHILADELPHIA, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating [...]
Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8:00 a.m. ET
27/10/2026
WARREN, N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a biopharmaceutical company advancing medicines to bring meaningful improvement to patients' [...]
Hormone-Free Menopause Supplement for Perimenopause Through Postmenopause Now Available From Calroy Health Sciences
27/10/2026
The daily formula pairs two ingredients, each with published research in women in mid-life or after menopause* Scottsdale, AZ, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Selentra HP™, powered by FEM-936™, a hormone-free [...]
Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026
27/10/2026
NEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that [...]
Satellos Establishes Scientific Advisory Board to Explore the Biology of Regeneration in Aging and Neuroscience
27/10/2026
Distinguished scientists bring expertise spanning stem cell biology, regenerative medicine, aging research, neuroscience and small molecule chemistry TORONTO, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. ( [...]
Tonix Pharmaceuticals Presented an Analysis of Phase 3 Data Demonstrating TONMYA® Improved Physical Symptoms and Functional Ability of Patients with Fibromyalgia at the IASP 2026 World Congress on Pain
27/10/2026
TONMYA improved Fibromyalgia Impact Questionnaire-Revised (FIQR) symptoms and function scores versus placebo in both domains at Week 14 in RELIEF and RESILIENT Phase 3 pivotal studies Tonix commercially launched TONMYA [...]
NeurAxis to Host Third Quarter 2026 Results and Business Update Call on Monday, November 9, 2026
27/10/2026
CARMEL, Ind., Oct. 27, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and [...]
Repligen Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance
27/10/2026
Third quarter revenue of $209 million, a year-over-year increase of 11% as reported and 12.5% organic Closed BioLife acquisition, which fast-tracks Repligen’s leadership and offering in high-growth cell therapy market [...]
Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants
27/10/2026
WAYNE, Pa., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today [...]

Pages